Tokio Marine Asset Management Co. Ltd. Acquires Shares of 3,400 GW Pharmaceuticals PLC- (GWPH)

Tokio Marine Asset Management Co. Ltd. acquired a new position in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) during the first quarter, Holdings Channel reports. The firm acquired 3,400 shares of the biopharmaceutical company’s stock, valued at approximately $411,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in GWPH. Scopia Capital Management LP acquired a new position in GW Pharmaceuticals PLC- during the third quarter worth $250,218,000. Prudential PLC increased its stake in shares of GW Pharmaceuticals PLC- by 75.8% in the fourth quarter. Prudential PLC now owns 2,050,212 shares of the biopharmaceutical company’s stock valued at $229,111,000 after buying an additional 884,106 shares in the last quarter. Redmile Group LLC purchased a new stake in shares of GW Pharmaceuticals PLC- during the third quarter valued at approximately $72,460,000. Capital Research Global Investors increased its stake in shares of GW Pharmaceuticals PLC- by 14.9% in the third quarter. Capital Research Global Investors now owns 3,017,604 shares of the biopharmaceutical company’s stock valued at $400,527,000 after buying an additional 390,930 shares in the last quarter. Finally, Orbimed Advisors LLC increased its stake in shares of GW Pharmaceuticals PLC- by 995.6% in the fourth quarter. Orbimed Advisors LLC now owns 396,600 shares of the biopharmaceutical company’s stock valued at $44,320,000 after buying an additional 360,400 shares in the last quarter. 72.30% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

GW Pharmaceuticals PLC- (NASDAQ:GWPH) traded up 1.90% during trading on Friday, hitting $106.27. 360,526 shares of the stock traded hands. The company’s market cap is $2.69 billion. GW Pharmaceuticals PLC- has a 52-week low of $79.62 and a 52-week high of $137.88. The firm has a 50-day moving average price of $113.56 and a 200 day moving average price of $118.89.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.50) by $0.20. GW Pharmaceuticals PLC- had a negative net margin of 702.90% and a negative return on equity of 20.07%. The business had revenue of $2.04 million for the quarter, compared to analysts’ expectations of $2.07 million. During the same period in the previous year, the company earned ($0.06) EPS. GW Pharmaceuticals PLC-‘s revenue for the quarter was down 23.0% compared to the same quarter last year. On average, equities analysts expect that GW Pharmaceuticals PLC- will post ($5.53) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was originally reported by Mideast Time and is the property of of Mideast Time. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.mideasttime.com/tokio-marine-asset-management-co-ltd-acquires-shares-of-3400-gw-pharmaceuticals-plc-gwph/1708717.html.

Several brokerages have recently commented on GWPH. Goldman Sachs Group Inc reiterated a “buy” rating and issued a $185.00 target price on shares of GW Pharmaceuticals PLC- in a report on Wednesday, February 22nd. TheStreet upgraded shares of GW Pharmaceuticals PLC- from a “d+” rating to a “c-” rating in a report on Tuesday, March 14th. Cantor Fitzgerald set a $208.00 target price on shares of GW Pharmaceuticals PLC- and gave the company a “buy” rating in a report on Tuesday, February 7th. Piper Jaffray Companies set a $147.00 target price on shares of GW Pharmaceuticals PLC- and gave the company a “buy” rating in a report on Tuesday, February 7th. Finally, Cowen and Company set a $135.00 target price on shares of GW Pharmaceuticals PLC- and gave the company a “buy” rating in a report on Monday, February 6th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $144.50.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

5 Day Chart for NASDAQ:GWPH

Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.